Generating protective immunity against genital herpes

Trends in Immunology

Volumn 34, Issue 10, 2013, Pages 487-494

  Shin, Haina ^a   Iwasaki, Akiko ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibodies; Cell migration; Female genital tract; Memory T cells; Protective immunity; Vaccines

Indexed keywords

GLYCOPROTEIN B; GLYCOPROTEIN D;

ADAPTIVE IMMUNITY; GENITAL HERPES; HERPES SIMPLEX VIRUS 2; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INNATE IMMUNITY; NERVOUS SYSTEM; NONHUMAN; PATHOGENESIS; REVIEW;

ANTIBODIES; CELL MIGRATION; FEMALE GENITAL TRACT; MEMORY T CELLS; PROTECTIVE IMMUNITY; VACCINES;

ANIMALS; HERPES GENITALIS; HUMANS; VIRAL VACCINES;

EID: 84884815297     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2013.08.001     Document Type: Review

References (78)

1. Looker K.J., et al. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull. World Health Organ. 2008, 86:737-816.
2. Centers for Disease Control Seroprevalence of herpes simplex virus type 2 among persons aged 14-49 years - United States, 2005-2008. Morb. Mortal. Wkly. Rep. 2008, 59:456-459.
3. Johnston C., et al. Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials. Lancet 2012, 379:641-647.
4. Johnston C., et al. HSV-2: in pursuit of a vaccine. J. Clin. Invest. 2011, 121:4600-4609.
5. Roth K., et al. HSV-2 vaccine: current state and insights into development of a vaccine that targets genital mucosal protection. Microb. Pathog. 2013, 58:45-54.
6. Campadelli-Fiume G., et al. Viral and cellular contributions to herpes simplex virus entry into the cell. Curr. Opin. Virol. 2012, 2:28-36.
7. Knipe D.M., Cliffe A. Chromatin control of herpes simplex virus lytic and latent infection. Nat. Rev. Microbiol. 2008, 6:211-221.
8. Smith G. Herpesvirus transport to the nervous system and back again. Annu. Rev. Microbiol. 2012, 66:153-176.
9. Wilson A.C., Mohr I. A cultured affair: HSV latency and reactivation in neurons. Trends Microbiol. 2012, 20:604-611.
10. Koelle D.M., Corey L. Herpes simplex: insights on pathogenesis and possible vaccines. Annu. Rev. Med. 2008, 59:381-395.
11. Schiffer J.T., et al. Rapid localized spread and immunologic containment define Herpes simplex virus-2 reactivation in the human genital tract. eLife 2013, 2:e00288.
12. Wald A., et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N. Engl. J. Med. 2000, 342:844-950.
13. Tronstein E., et al. Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection. JAMA 2011, 305:1441-1449.
14. Schiffer J.T., et al. Frequent release of low amounts of herpes simplex virus from neurons: results of a mathematical model. Sci. Transl. Med. 2009, 1:7ra16.
15. Paludan S.R., et al. Recognition of herpesviruses by the innate immune system. Nat. Rev. Immunol. 2011, 11:143-154.
16. Cai M., et al. The herpes simplex virus 1-encoded envelope glycoprotein B activates NF-κB through the Toll-like receptor 2 and MyD88/TRAF6-dependent signaling pathway. PLoS ONE 2013, 8:e54586.
17. Unterholzner L., et al. IFI16 is an innate immune sensor for intracellular DNA. Nat. Immunol. 2010, 11:997-1004.
18. Orzalli M.H., et al. Nuclear IFI16 induction of IRF-3 signaling during herpesviral infection and degradation of IFI16 by the viral ICP0 protein. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:E3008-E3017.
19. Li T., et al. Acetylation modulates cellular distribution and DNA sensing ability of interferon-inducible protein IFI16. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:10558-10563.
20. Conrady C.D., et al. Resistance to HSV-1 infection in the epithelium resides with the novel innate sensor, IFI-16. Mucosal Immunol. 2012, 5:173-183.
21. Chiu Y-H., et al. RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway. Cell 2009, 138:576-591.
22. Sun L., et al. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 2013, 339:786-791.
23. Wu J., et al. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science 2013, 339:826-830.
24. Rathinam V.A.K., et al. The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat. Immunol. 2010, 11:395-402.
25. Johnson K.E., et al. Herpes simplex virus 1 infection induces activation and subsequent inhibition of the IFI16 and NLRP3 inflammasomes. J. Virol. 2013, 87:5005-5018.
26. Holm C.K., et al. Virus-cell fusion as a trigger of innate immunity dependent on the adaptor STING. Nat. Immunol. 2012, 13:737-743.
27. Sato A., et al. Induction of antiviral immunity requires Toll-like receptor signaling in both stromal and dendritic cell compartments. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:16274-21629.
28. Iwasaki A. Mucosal dendritic cells. Annu. Rev. Immunol. 2007, 25:381-418.
29. Lee H.K., et al. Differential roles of migratory and resident DCs in T cell priming after mucosal or skin HSV-1 infection. J. Exp. Med. 2009, 206:359-370.
30. Heath W.R., Carbone F.R. Dendritic cell subsets in primary and secondary T cell responses at body surfaces. Nat. Immunol. 2009, 10:1237-1244.
31. + T-cell help. Nature 2009, 462:510-513.
32. Lund J.M., et al. Coordination of early protective immunity to viral infection by regulatory T cells. Science 2008, 320:1220-1224.
33. Schiffer J.T., Corey L. Rapid host immune response and viral dynamics in herpes simplex virus-2 infection. Nat. Med. 2013, 19:280-288.
34. + skin-resident T cells in human herpes virus infection. Nature 2013, 497:494-497.
35. Schiffer J.T., et al. Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:18973-18978.
36. + T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J. Exp. Med. 2007, 204:595-603.
37. Goethals S., et al. Toll-like receptor expression in the peripheral nerve. Glia 2010, 58:1701-1709.
38. Sancho-Shimizu V., et al. Inborn errors of anti-viral interferon immunity in humans. Curr. Opin. Virol. 2011, 1:487-496.
39. Reinert L.S., et al. TLR3 deficiency renders astrocytes permissive to herpes simplex virus infection and facilitates establishment of CNS infection in mice. J. Clin. Invest. 2012, 122:1368-1376.
40. Lafaille F.G., et al. Impaired intrinsic immunity to HSV-1 in human iPSC-derived TLR3-deficient CNS cells. Nature 2012, 491:769-773.
41. Orvedahl A., et al. Autophagy protects against Sindbis virus infection of the central nervous system. Cell Host Microbe 2010, 7:115-127.
42. Yordy B., et al. A neuron-specific role for autophagy in antiviral defense against herpes simplex virus. Cell Host Microbe 2012, 12:334-345.
43. + T cells are selectively activated and retained in latently infected sensory ganglia. Immunity 2003, 18:593-603.
44. Wakim L.M., et al. Dendritic cell-induced memory T cell activation in nonlymphoid tissues. Science 2008, 319:198-202.
45. + T cells patrol HSV-1-infected trigeminal ganglia and prevent viral reactivation. J. Neurovirol. 2011, 17:528-534.
46. + T cell inhibition of HSV-1 reactivation from neuronal latency. Science 2008, 322:268-271.
47. Wherry E.J. T cell exhaustion. Nat. Immunol. 2011, 12:492-499.
48. Mackay L.K., et al. Maintenance of T cell function in the face of chronic antigen stimulation and repeated reactivation for a latent virus infection. J. Immunol. 2012, 188:2173-2178.
49. + T cells in latently infected trigeminal ganglia: a novel immune evasion mechanism. J. Virol. 2011, 85:9127-9138.
50. Iijima N., et al. Dendritic cells and B cells maximize mucosal Th1 memory response to herpes simplex virus. J. Exp. Med. 2008, 205:3041-3052.
51. + T cells. Nature 2011, 477:216-219.
52. Morrison L.A. Replication-defective virus vaccine-induced protection of mice from genital herpes simplex virus 2 requires CD4 T cells. Virology 2008, 376:205-210.
53. Johnson A.J., et al. Herpes simplex virus (HSV)-specific T cells activated in the absence of IFN-gamma express alternative effector functions but are not protective against genital HSV-2 infection. J. Reprod. Immunol. 2010, 84:8-15.
54. Gebhardt T., et al. Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. Nat. Immunol. 2009, 10:524-530.
55. Shin H., Iwasaki A. A vaccine strategy that protects against genital herpes by establishing local memory T cells. Nature 2012, 491:463-467.
56. + T cells in innate and adaptive immune control of genital herpes simplex virus type 2 infection in mice. J. Gen. Virol. 2001, 82:845-853.
57. Li Z., et al. Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:4388-4393.
58. Corey L., et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. JAMA 1999, 282:331-340.
59. Stanberry L.R., et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 2002, 347:1652-1661.
60. Belshe R.B., et al. Efficacy results of a trial of a herpes simplex vaccine. N. Engl. J. Med. 2012, 366:34-43.
61. Iwasaki A. Antiviral immune responses in the genital tract: clues for vaccines. Nat. Rev. Immunol. 2010, 10:699-711.
62. Mackay L.K., et al. Long-lived epithelial immunity by tissue-resident memory T (TRM) cells in the absence of persisting local antigen presentation. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:7037-7042.
63. + TRM cells providing global skin immunity. Nature 2012, 483:227-231.
64. Teijaro J.R., et al. Cutting edge: tissue-retentive lung memory CD4 T cells mediate optimal protection to respiratory virus infection. J. Immunol. 2011, 187:5510-5514.
65. Bomsel M., et al. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 2011, 34:269-280.
66. Cattamanchi A., et al. Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system. Clin. Vaccine Immunol. 2008, 15:1638-1643.
67. Dudek T., et al. Disruption of the UL41 gene in the herpes simplex virus 2 dl5-29 mutant increases its immunogenicity and protective capacity in a murine model of genital herpes. Virology 2008, 372:165-175.
68. Hoshino Y., et al. Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs. J. Infect. Dis. 2009, 200:1088-1095.
69. de Bruyn G., et al. A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects. Vaccine 2006, 24:914-920.
70. Skoberne M., et al. An adjuvanted herpes simplex virus 2 subunit vaccine elicits a T cell response in mice and is an effective therapeutic vaccine in guinea pigs. J. Virol. 2013, 87:3930-3942.
71. + cellular immunity and protective efficacy. Vaccine 2011, 29:8530-8541.
72. Wald A., et al. Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons. Vaccine 2011, 29:8520-8529.
73. Parr M.B., Parr E.L. Protective immunity against HSV-2 in the mouse vagina. J. Reprod. Immunol. 1997, 36:77-92.
74. Gallichan W.S., Rosenthal K.L. Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization. J. Exp. Med. 1996, 184:1879-1890.
75. Morrison L.A., et al. Influence of mucosal and parenteral immunization with a replication-defective mutant of HSV-2 on immune responses and protection from genital challenge. Virology 1998, 243:178-187.
76. Ye L., et al. Efficient mucosal vaccination mediated by the neonatal Fc receptor. Nat. Biotechnol. 2011, 29:158-163.
77. Corti D., Lanzavecchia A. Broadly neutralizing antiviral antibodies. Annu. Rev. Immunol. 2013, 31:705-742.
78. Qi J., et al. Painful Pathways Induced by TLR Stimulation of Dorsal Root Ganglion Neurons. The Journal of Immunology 2011, 186:6417-6426.